Figure 1

Time-to-development of grade ≥III hepatotoxicity among naïve (1a) and experienced (1b) patient groups stratified by type of antiretroviral treatment regimens prescribed. Continuous lines represent patients prescribed HIV-1 non nucleoside reverse transcriptase inhibitors; dotted lines represent patients prescribed single HIV-1 protease inhibitor regimens; dashed lines represent patients prescribed multiple HIV-1 protease inhibitor regimens. P: 0.16 for comparison across antiretroviral naïve patients prescribed different regimens (see panel 1a); P: 0.027 for comparison across antiretroviral experienced patients prescribed different regimens (panel 1b).